STAT+: Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings
Plus more biotech news of the day, brought to you by The Readout.
Previous Post
Community Health Centers Expand Lp(a) Screening to Reduce Cardiovascular Risk
Next Post
Integrating Dermatologists Into Medical Teams Can Improve Patient Outcomes: Hadar Avihai Lev-Tov, MD
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago